Journal of

Infusion Nursing The Art and Science of Infusion Nursing

LETTER TO THE EDITOR

A Missed Opportunity Dear Editor, We agree with the principles described by Younger et al in “Subcutaneous Immunoglobulin Replacement Therapy: Ensuring Success.”1 In particular, it is important to have a “patient-specific regimen that will meet each patient’s needs” and that the way to do this is to go through the questions they describe regarding length and frequency of infusion, number of needles, and pump usage. We do feel, however, that the article missed an opportunity to fully describe the range of immunoglobulin (Ig) options available for treating adult patients with primary immunodeficiency (PI). Unfortunately, omitted in the discussion was the mention of HyQvia (immune globulin 10% with recombinant human hyaluronidase [rHuPH20]), a novel facilitated subcutaneous immunoglobulin (IgSC) recently approved in both the United States and Europe for the treatment of PI in adults.2-5 While IgSC is an excellent alternative to intravenous immunoglobulin (IgIV), the major limitations and treatment burden of conventional IgSC are the need to use several infusion sites (1-8) to administer a single dose and the need to dose frequently (daily to biweekly). HyQvia overcomes these barriers by enabling the delivery of up to a full monthly therapeutic dose (up to 600 mL/infusion site) of Ig via 1 to 2 SC infusion site(s). This is possible because rHuPH20 (the enzyme administered as part of the treatment) mimics the naturally occurring enzyme hyaluronidase, depolymerizing the gel-like hyaluronanan and increasing the dispersion of fluid in the SC tissue. rHuPH20 acts locally and transiently as a spreading factor to reversibly modify the SC tissue and makes it possible to increase the volume and flow rates of Ig into the local SC space.6 Thus, HyQvia enables patients to receive Ig treatment at an infusion frequency and rate similar to IgIV but with better systemic tolerability compared with IgIV. HyQvia was approved on the basis of a pivotal Phase 3 study and a subsequent extension study, which together provide up to 3.5 years of safety data.5,7,8 The efficacy data indicate that the rate of serious bacterial infections in PI patients was well below the regulatory requirement of less than 1 per patient year. Safety data indicate that HyQvia was well tolerated with no serious adverse reactions reported after up to 3.5 years of treatment.

Conflict of interest: The authors of this letter are all employees of Baxter Healthcare Corporation. DOI: 10.1097/NAN.0000000000000115

252  Copyright © 2015 Infusion Nurses Society

Journal of Infusion Nursing

Copyright © 2015 Infusion Nurses Society. Unauthorized reproduction of this article is prohibited.

JIN-D-15-00012.indd 252

22/06/15 9:00 PM

Local adverse reactions were comparable to those observed in conventional IgSC studies despite 20- to 30-fold greater volumes per site and 10- to 15-fold greater infusion rates than those administered with conventional IgSC. While 18% of patients developed antibodies to rHuPH20 (with no clinical consequences and with declining titer levels over time), no patients developed neutralizing antibodies to rHuPH20. In summary, the data indicate that HyQvia provides IgG replacement therapy that meets the standards for IgG replacement therapies. As indicated in the FDA-approved US prescribing information, patients are converted from IgIV to HyQvia at the same dose (100%) as their previous IgIV treatment (ie, 1-to-1 conversion). A direct conversion is possible because of the increased bioavailability of Ig when delivered using HyQvia. In contrast, a dose increase of 137% is required with conventional IgSC. The recent approval of HyQvia increases the treatment options available to patients with PI, allowing for greater possibilities to plan a patient-specific regimen that meets each patient’s needs. All the characteristics of HyQvia mentioned above make it possible to combine the best features of IgSC and IgIV to decrease the lifelong treatment burden and optimize the treatment experience for adult patients with PI. Leon Rozen, MBBS, FRCPA, AFRACMA Kim Duff, BSN, RN Catherine Taggart, MBA, RN, CRNI® Jeanette Scott, BSN, RN

References 1. Younger ME, Blouin W, Duff C, Epland KB, Murphy E, Sedlak D. Subcutaneous immunoglobulin replacement therapy: ensuring success. J Infus Nurs. 2015;38(1):70-79. 2. HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] prescribing information Westlake Village, CA: Baxter Healthcare Corp; 2014. http:// www.baxter.com/downloads/healthcare_professionals/products/ HyQvia_PI.pdf. Accessed February 3, 2015. 3. European Medicines Agency. Annex I: Summary of Product Characteristics [HyQvia 100 mg/mL]. London, UK. http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/002491/WC500143851.pdf. Published May 2013. Accessed March 6, 2015. 4. Sanford M. Human immunoglobulin 10% with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders. BioDrugs. 2014;28(4):411-420. 5. Wasserman RL. Overview of recombinant human hyaluronidasefacilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy. 2014;6(5):553-567. 6. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427-440. 7. Wasserman RL, Melamed I, Stein MR, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951-957.e11. 8. Wasserman RL, Stein MR, Melamed I, et al. Long-term efficacy and safety of recombinant human hyaluronidase (rHuPH20)facilitated subcutaneous infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in patients with primary immunodeficiencies (PI). J Allergy Clin Immunol. 2015;135(2):AB96.

Author Response: The authors appreciate the comment and agree that there are a wide range of options for immunoglobulin replacement therapy. Unfortunately, HyQvia, or facilitated immunoglobulin, was approved by the Food and Drug Administration in September 2014, after this article had been accepted and gone to press. A discussion of facilitated immunoglobulin was not “an opportunity missed” but rather an opportunity not available when the article was written. M. Elizabeth Younger, PhD, CRNP June 11, 2015

VOLUME 38  |  NUMBER 4  |  JULY/AUGUST 2015

Copyright © 2015 Infusion Nurses Society  253

Copyright © 2015 Infusion Nurses Society. Unauthorized reproduction of this article is prohibited.

JIN-D-15-00012.indd 253

22/06/15 9:00 PM

A Missed Opportunity.

A Missed Opportunity. - PDF Download Free
184KB Sizes 4 Downloads 15 Views